Incretins: a new approachLEFEBVRE, P.Diabetes & metabolism. 2008, Vol 34, issn 1262-3636, 57 p., SUP2Serial Issue

Pancreatic α-cell dysfunction in diabetesBURCELIN, R; KNAUF, C; CANI, P. D et al.Diabetes & metabolism. 2008, Vol 34, issn 1262-3636, S49-S55, SUP2Article

β-cell apoptosis in type 2 diabetes : quantitative and functional consequencesLUPI, R; DEL PRATO, S.Diabetes & metabolism. 2008, Vol 34, issn 1262-3636, S56-S64, SUP2Article

Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetesGAUTIER, J.-F; CHOUKEM, S.-P; GIRARD, J et al.Diabetes & metabolism. 2008, Vol 34, issn 1262-3636, S65-S72, SUP2Article

GLP-1 receptor signaling : effects on pancreatic β-cell proliferation and survivalBUTEAU, J.Diabetes & metabolism. 2008, Vol 34, issn 1262-3636, S73-S77, SUP2Article

Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapiesPENFORNIS, A; BOROT, S; RACCAH, D et al.Diabetes & metabolism. 2008, Vol 34, issn 1262-3636, S78-S90, SUP2Article

Abnormalities in insulin secretion in type 2 diabetes mellitusGUILLAUSSEAU, P.-J; MEAS, T; VIRALLY, M et al.Diabetes & metabolism. 2008, Vol 34, issn 1262-3636, S43-S48, SUP2Article

DPP-4 inhibitors and GLP-1 analogues : for whom? Which place for incretins in the management of type 2 diabetic patients?HALIMI, S.Diabetes & metabolism. 2008, Vol 34, issn 1262-3636, S91-S95, SUP2Article